IP Library Granted Patent US 7,875,602
Granted Patent B2
US 7,875,602 · App. 11/444,150 · Granted Jan 25, 2011

Camptothecin derivatives as chemoradiosensitizing agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,875,602
App. No.
11/444,150
Granted
Jan 25, 2011
Kind
B2
Abstract

Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

Claims (84)

1. A compound of the formula (II) or a pharmaceutically acceptable salt thereof,

wherein X is a covalent bond;

Y is ═NO—, —N(H)O—, ═N— or S;

T is independently CRR′;

each of R and R′ is independently selected from hydrogen, C1-4 alkyl, and substituted C1-4 alkyl;

n is an integer from 0 to 8;

R 1 is fluorenyl optionally substituted with at least one nitro group;

R 2 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, tri lower alkylsilyl, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, O-quinone, substituted lower alkyl aminomethyl, lower alkylcarbonylamino, lower alkylcarbonyloxy methyl, optionally substituted lower alkylcarbonyloxy methyl, substituted vinyl, 1-hydroxy-2-nitroethyl, alkoxycarbonylethyl, aminocarbonyl, alkylcarbonyl, alkylcarbonyloxymethyl, benzoylmethyl, benzylcarbonyloxymethyl, lower alkyliminomethyl and lower alkoxymethyl;

R 3 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, CH 2 NR 7 R 8 (where each of R 7 and R 8 is independently H, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R 7 and R 8 taken together with —N— represent a cyclic amino-), CH 2 R 9 (where R 9 is lower alkoxy, CN, amino lower alkoxy, mono- or di-lower alkylamino lower alkoxy, lower alkylthio, amino lower alkylthio, or mono- or di-lower alkylamino lower alkylthio), NR 10 R 11 (where each of R 10 and R 11 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, or amino lower alkyl, or R 10 and R 11 taken together with —N— represent a cyclic amino), trialkylsilyl, dialkylamino alkyl, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, O-quinone, substituted lower alkyl aminomethyl, and lower alkylcarbonylamino; or R 3 together with R 4 is furan, dihydrofuran or 1,4-oxazine-2-one;

R 4 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, amino lower alkyl, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, O-quinone, substituted lower alkyl aminomethyl, and lower alkylcarbonylamino, or R 4 together with R 3 is furan, dihydrofuran or 1,4-oxazine-2-one, or R 4 together with R 5 is methylenedioxy;

R 5 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, O-quinone, substituted lower alkyl aminomethyl, and lower alkylcarbonylamino; and

R 6 is selected from the group consisting of hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, trialkylsilyl, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, O-quinone, substituted lower alkyl aminomethyl, and lower alkylcarbonylamino;

wherein

substituted C1-4 alkyl is an alkyl group having 1 to 4 carbons and one to five substituents independently selected from the group consisting of halo, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

substituted lower alkyl is an alkyl group having 1 to 6 carbons and one to five substituents independently selected from the group consisting of halo, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

substituted lower alkyl aminomethyl is a monovalent radical having the formula —CH 2 NHAlk, where Alk is a substituted lower alkyl;

optionally substituted lower alkylcarbonyloxy methyl is a monovalent —CH 2 C(O)(loweralkyl) radical, wherein the loweralkyl is optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

substituted vinyl is —CH═CH 2 group substituted with one to three substituents independently selected from the group consisting of alkyl, halo, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

optionally substituted phenyl is phenyl optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperidino, lower alkoxycarbonyl, and lower alkylcarbonylamino;

optionally substituted carbocyclic is carbocyclic optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, sugar and phosphosugar,

optionally substituted heterocyclic, is heterocyclic optionally substituted with one or two substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, sugar and phosphosugar;

optionally substituted piperidino is piperidino optionally substituted with one or two substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, sugar and phosphosugar; and

optionally substituted fused 2-, 3- or 4-ring heterocyclic is fused 2-, 3- or 4-ring heterocyclic optionally substituted with one or five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, phenyl, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, sugar and phosphosugar.

2. The compound of claim 1 , wherein Y is ═NO— or —N(H)O—.

3. The compound of claim 2 , wherein n is 1 and each of R and R′ is independently methyl or hydrogen.

4. The compound of claim 3 , wherein R 1 is 9-fluorenyl optionally substituted with at least one nitro group.

5. The compound of claim 4 wherein the compound is selected from the group consisting of:

6. The compound of claim 4 , wherein the 9-fluorenyl is substituted with at least one nitro group.

7. The compound of claim 6 , wherein R 1 is

8. The compound of claim 7 wherein the compound is selected from the group consisting of:

9. A compound of claim 1 , wherein R 1 Y-(T) n -X—C(O)O— is

10. The compound according to claim 1 , wherein

R 2 is hydrogen;

R 3 is CH 2 NR 7 R 8 (where each of R 7 and R 8 is independently H, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R 7 and R 8 taken together with —N— represent a cyclic amino-), NR 10 R 11 (where each of R 10 and R 11 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, or amino lower alkyl, or R 10 and R 11 taken together with —N— represent a cyclic amino), or dialkylamino alkyl;

R 4 is lower alkoxy, hydroxy, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, or R 4 together with R 5 is methylenedioxy;

R 5 is hydrogen or together with R 4 is methylenedioxy; and

R 6 is hydrogen.

11. The compound of claim 10 , wherein R 3 is CH 2 NR 7 R 8 (where each of R 7 and R 8 is lower alkyl), R 4 is hydroxy, alkoxy, lower alkoxycarbonyloxy or alkylcarbonyloxy, and R 5 is hydrogen.

12. The compound of claim 11 , wherein R 3 is CH 2 N(CH 3 ) 2 .

13. The compound of claim 12 , wherein R 4 is hydroxy.

14. The compound of claim 1 , wherein

R 2 is hydrogen, lower alkyl or halogenated lower alkyl;

R 3 is hydrogen or lower alkyl;

R 4 is lower alkoxy, hydroxy, halogenated lower alkoxy, hydroxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, phosphosugar, or R 4 together with R 5 is methylenedioxy;

R 5 is hydrogen or together with R 4 is methylenedioxy; and

R 6 is hydrogen.

15. The compound of claim 14 , wherein R 3 is hydrogen, R 4 is carbamoyloxy, and R 5 is hydrogen.

16. The compound of claim 14 , wherein R 2 is lower alkyl and R 4 is 4-(1-piperidino)-1-piperidinocarbonyloxy.

17. The compound of claim 16 , wherein R 2 is ethyl.

18. The compound of claim 14 , wherein R 2 is hydrogen, and R 4 is 4-(1-piperidino)-1-piperidinocarbonyloxy.

19. The compound of claim 14 , wherein R 2 is hydrogen, R 3 is hydrogen and R 4 is tert-butyloxycarbonyloxy.

20. The compound of claim 1 , wherein

R 2 is lower alkyl;

R 3 is hydrogen;

R 4 is hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, or phosphosugar;

R 5 is hydrogen; and

R 6 is hydrogen.

21. The compound of claim 20 , wherein R 2 is ethyl and R 4 is hydroxy.

22. The compound of claim 1 , wherein each of R 2 , R 4 , R 5 and R 6 is hydrogen and R 3 is amino or nitro.

23. The compound of claim 22 , wherein R 3 is amino.

24. The compound of claim 22 , wherein R 3 is nitro.

25. The compound of claim 1 , wherein

R 2 is tri-lower alkylsilyl;

R 3 is hydrogen;

R 4 is hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, lower alkoxycarbonyloxy, sugar, or phosphosugar;

R 5 is hydrogen; and

R 6 is hydrogen.

26. The compound of claim 25 , wherein R 2 is t-butyldimethylsilyl and R 4 is hydroxy.

27. A composition comprising a compound according to claim 1 , together with a pharmaceutically acceptable excipient.

28. The compound of claim 1 , wherein one of the R 2 , R 4 , or R 5 is selected from the group consisting of (tris(hydroxymethyl)methylamino)methyl, (bis(hydroxymethyl)methylamino)methyl, and (2-hydroxyethylamino)methyl.

29. The compound of claim 28 , wherein R 2 is selected from the group consisting of (tris(hydroxymethyl)methylamino)methyl, (bis(hydroxymethyl)methylamino)methyl, and (2-hydroxyethylamino)methyl.

30. The compound of claim 29 ,

wherein

R 3 is hydrogen, dimethylamino, amino, or nitro;

R 4 is hydrogen, hydroxy, or 4-(1-piperidino)-1-piperidinocarbonyloxy; or

R 4 together with R 5 is methylenedioxy;

R 5 is hydrogen; or

R 5 together with R 4 is methylenedioxy; and

R 6 is hydrogen.

31. The compound of claim 30 ,

wherein

R 3 is hydrogen; and

R 4 together with R 5 is methylenedioxy.

32. The compound of claim 30 , wherein each of R 3 , R 4 , and R 5 is hydrogen.

Assignments (4)
LICENSE Recorded May 16, 2013
From: CALIFORNIA PACIFIC MEDICAL CENTER; CATHOLIC HEALTHCARE WEST
To: TLC BIOPHARMACEUTICALS, INC., A SUBSIDIARY OF TAIWAN LIPOSOME COMPANY, LTD.
Reel/Frame 030431/0554 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS FROM 475 BRANNAN STREET, SUITE 200, SAN FRANCISCO, CA 94107 PREVIOUSLY RECORDED ON REEL 023180 FRAME 0332. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE'S ADDRESS TO BE 475 BRANNAN STREET, SUITE 220, SAN FRANCISCO, CA 94107. Recorded Dec 29, 2009
From: CALIFORNIA PACIFIC MEDICAL CENTER
To: SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER
Reel/Frame 023715/0749 →
CHANGE OF NAME Recorded Sep 2, 2009
From: CALIFORNIA PACIFIC MEDICAL CENTER
To: SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER
Reel/Frame 023180/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2006
From: YANG, LI-XI
To: CALIFORNIA PACIFIC MEDICAL CENTER; CATHOLIC HEALTHCARE WEST DBA ST. MARY'S MEDICAL CENTER
Reel/Frame 018153/0615 →